aTyr Pharma investors may have been misled about Efzofitimod's efficacy.

A law firm is issuing a notice to shareholders of aTyr Pharma, Inc. regarding possible lead plaintiff appointment for a class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the efficacy of Efzofitimod, a drug intended to allow patients to taper off steroids. The truth emerged when the company hosted an investor call announcing the drug's results. Shareholders who purchased ATYR shares during the class period are encouraged to contact the firm.